Showing results (1581-1590 of 2,519) with videos related to

Sort By:
Pageof 252
The Journal of Experimental Medicine|October 27, 2019
Cell type-specific actions of Bcl11b in early T-lineage and group 2 innate lymphoid cellsHiroyuki Hosokawa, Maile Romero-Wolf, Qi Yang, et al.
Allergy|February 16, 2023
Protease allergens as initiators-regulators of allergic inflammationWai Tuck Soh, Jihui Zhang, Morley D Hollenberg, et al.
The Journal of Biological Chemistry|September 25, 1988
Characterization of a human eosinophil proteoglycan, and augmentation of its biosynthesis and size by interleukin 3, interleukin 5, and granulocyte/macrophage colony stimulating factorM E Rothenberg, J L Pomerantz, W F Owen, et al.
Blood|January 19, 2006
The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like diseaseYoshiyuki Yamada, Marc E Rothenberg, Andrew W Lee, et al.
The Journal of Allergy and Clinical Immunology|April 16, 2008
Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levelsMiguel L Stein, Joyce M Villanueva, Bridget K Buckmeier, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1994
Preclinical and phase I trials of topoisomerase I inhibitorsD D Von Hoff, H A Burris, J Eckardt, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|August 9, 2020
Early life factors are associated with risk for eosinophilic esophagitis diagnosed in adulthoodEvan S Dellon, Olivia Shaheen, Nathaniel T Koutlas, et al.
Plos One|January 13, 2022
Emergency department utilization for substance use disorders and mental health conditions during COVID-19Arjun K Venkatesh, Alexander T Janke, Jeremy Kinsman, et al.
Elife|January 15, 2020
Ankyrin-G mediates targeting of both Na+ and KATP channels to the rat cardiac intercalated discHua-Qian Yang, Marta Pérez-Hernández, Jose Sanchez-Alonso, et al.
Plos One|August 29, 2014
Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetesSue Sha, Damayanthi Devineni, Atalanta Ghosh, et al.
Pageof 252